Cargando…

Predicting Axillary Response in Hormone Receptor-Positive Breast Cancer after Neoadjuvant Chemotherapy Using Real-World Data

PURPOSE: To develop a scoring system for hormone receptor-positive (HR+) breast cancer patients who are expected to achieve axillary pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). To confirm the correlation between axillary status and survival rate in HR+ breast cancer af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Jie, Zheng, Yiwen, Qian, Da, Guan, Dandan, Zheng, Qinghui, Xu, Yuhao, Ju, Siyi, Meng, Xuli, Tang, Hongchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797309/ https://www.ncbi.nlm.nih.gov/pubmed/36590310 http://dx.doi.org/10.1155/2022/6972703

Ejemplares similares

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China
por: Guan, Dandan, et al.
Publicado: (2022)

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Xu, Yuhao, et al.
Publicado: (2022)

Prediction of axillary response after neoadjuvant chemotherapy in clinical node positive breast cancer
por: Zheng, Weizhen, et al.
Publicado: (2021)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Role of Axillary Surgery After Neoadjuvant Chemotherapy
por: Cavalcante, Francisco Pimentel, et al.
Publicado: (2020)

Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer
por: Ladak, Farah, et al.
Publicado: (2022)

Targeted axillary biopsy and sentinel lymph node biopsy for axillary restaging after neoadjuvant chemotherapy
por: Gurleyik, Gunay, et al.
Publicado: (2021)

Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
por: Liu, Shuyan, et al.
Publicado: (2023)

Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2017)

Marking Techniques for Targeted Axillary Dissection Among Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy
por: Gante, Inês, et al.
Publicado: (2023)

Radiographic identification of a positive clipped axillary lymph node in a mastectomy specimen following neoadjuvant chemotherapy
por: Seto, Andrew, et al.
Publicado: (2023)

Axillary and internal mammary sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy
por: Cao, Xiao-Shan, et al.
Publicado: (2016)

Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer
por: Liu, Xiaozhen, et al.
Publicado: (2018)

Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis
por: Choi, Hee Jun, et al.
Publicado: (2018)

Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer
por: Choi, Hee Jun, et al.
Publicado: (2019)

Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy
por: Wang, Wenyan, et al.
Publicado: (2022)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay
por: Lee, Jun-Hee, et al.
Publicado: (2022)

Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
por: Choi, Hee Jun, et al.
Publicado: (2022)

Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients
por: Ye, Bei-Bei, et al.
Publicado: (2016)

The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy
por: Reitsamer, R., et al.
Publicado: (2021)

Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
por: Wang, Mengshen, et al.
Publicado: (2020)

Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
por: Kim, Jee Ye, et al.
Publicado: (2015)

Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy
por: Chen, Shin-Cheh, et al.
Publicado: (2021)

Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study
por: Hartmann, Steffi, et al.
Publicado: (2022)

Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
por: Yang, Libo, et al.
Publicado: (2018)

Hyperglycemia and Chemoresistance in Breast Cancer: From Cellular Mechanisms to Treatment Response
por: Qiu, Jie, et al.
Publicado: (2021)

Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection
por: Erbes, Thalia, et al.
Publicado: (2014)

Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients
por: Li, Zhuoxuan, et al.
Publicado: (2022)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer
por: Xu, Yuhao, et al.
Publicado: (2022)

A logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy
por: Şeber, Erdoğan Selçuk, et al.
Publicado: (2023)

Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node‐positive breast cancer: How can we select patients?
por: van Zeeland, Marianne, et al.
Publicado: (2020)

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
por: Maeshima, Yurina, et al.
Publicado: (2021)

Noninvasive prediction of node-positive breast cancer response to presurgical neoadjuvant chemotherapy therapy based on machine learning of axillary lymph node ultrasound
por: Zhang, Hao, et al.
Publicado: (2023)

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies
por: Vriens, Birgit E.P., et al.
Publicado: (2017)

Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer
por: Al-Hattali, Samia, et al.
Publicado: (2019)

Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
por: Chung, Yul Ri, et al.
Publicado: (2021)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_83vo3lbasrfqt33v2c6opca70q